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Antipolysaccharide antibodies directed at the capsular antigens of pathogenic 
bacteria  correlate  with  protection  against  infection  by these  organisms  (1-3). 
Antibody responses to most polysaccharides, however, develop late in ontogeny 
and do not reach adult levels until 8-12 wk in mice (4, 5) and 2-5 yr in man (6- 
8).  Although  conversion  of a  thymus-independent  (TI) 1 polysaccharide  (Ps) 
antigen to a thymus-dependent (TD) antigen has been shown to stimulate adult- 
level antibodies in  3-4-wk-old mice,  this  conjugate antigen  failed to  stimulate 
anti-Ps antibody responses in newborns (9). For this reason we have begun studies 
of alternative approaches to stimulating  anti-Ps antibody responses in neonatal 
mice. 
Rubinstein  et  al.  (10,  11)  have  shown  that  both  idiotype  (Id)  A48  (10),  a 
bacterial  levan  (BL)-binding  myeloma  protein,  and  anti-Id  (11),  when  given 
within 24 h after birth, can prime mice for an A48-dominant antibody response 
upon subsequent immunization with BL. Using this model, we have investigated 
the ability of Id  150C8,  an  IgM  monocional  antibody directed against  the  Ps 
capsule of Escherichia  coli  K13,  and  anti-Id  5868C,  an  IgG1  monoclonal  anti- 
150C8, to prime the immune system for protection against infection with E.  coli 
K13. We report here that administration of either Id or anti-Id within 24 h after 
birth can prime weanling mice for protection against E.  coli K 13 infection. 
Materials and Methods 
Animals.  Mice used in the immunization  experiments and the CAF~ mice used for the 
production of anti-Id  ascites were obtained from The Jackson Laboratory, Bar Harbor, 
ME. BALB/c mice used in the protection experiments were bred in the Animal House of 
the  Institute  of Medical  Microbiology,  University  of G6teborg,  from  breeding stocks 
obtained from the Chester Beatty Research Institute,  London, England.  Sprague-Dawley 
rats were obtained from Taconic Farms,  Inc., Germantown, NY. 
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Polysaccharides.  E. coli capsular Ps K1,  K13,  K20, and  K23 (Table I) were purified 
and characterized as described by Vann et al. (I 2, 13). E. coli K 1 Ps, a homopolymer of c~- 
(2 ~  8)-linked N-acetylneuraminic acid (NeuNAc), and K20 and K23 Ps were provided 
by Dr. Willie Vann. Haemophilus influenzae type b (HIB) capsular Ps and K13 Ps coupled 
to horsehoe crab hemocyanin (K 13-Hy) prepared as described (14) were provided by Dr. 
Rachel Schneerson. 
Bacteria.  E. coli strain 06:K13:H1, obtained from the Statens Seruminstitut,  Copen- 
hagen,  Denmark,  was grown  overnight in  liquid  medium containing  beef extract and 
peptone.  After overnight growth  the  cells were subcultured  in  the  same medium and 
grown to -5  x  108 cells/ml. A vaccine was prepared by inactivating the cells with 0.5% 
formalin  in  phosphate-buffered  saline  (PBS)  for  60  rain  at  room  temperature.  The 
concentration was adjusted to 1 ×  109/ml and the vaccine was stored at 4°C for up to  1 
wk. 
Cultures used for challenge with five bacteria were adjusted to the desired concentration 
in PBS and 0.5 ml was injected intraperitoneally per. mouse. Challenge doses were verified 
by direct plate count. In preliminary experiments the LDs0 for 4-5-wk-old BALB/c mice 
was determined to be 6 x  106 cells/mouse. 
Hybridomas.  Anti-K13  Ps  hybridomas were  prepared  in  BALB/cANN  mice as de- 
scribed by S6derstr6m et al.  (15).  One of those hybridomas,  150C8,  an IgM anti-K13, 
was used to prepare a monoclonal anti-Id antibody. A/HeJ mice were immunized with a 
complete Freund's adjuvant (CFA) emulsion of a precipitate formed by incubating 0.4 ml 
of 150C8-containing ascites with 0.4 ml of a  1 mg/ml solution of K13 Ps for 24-48 h in 
the cold. The resulting precipitates were pelleted by centrifugation, washed twice in PBS, 
resuspended in 0.4 mi PBS, and emulsified with 0.4 ml CFA containing H37Ra tubercle 
bacilli (Difco Laboratories, Inc., Detroit, MI). Mice were injected subcutaneously in the 
footpads (0.05  ml per footpad) and in the inguinal and axillary folds (0.025  ml in each 
region). The first injection was given in CFA and weekly injections thereafter were given 
in incomplete Freund's adjuvant (IFA).  1 d  after the seventh injection,  the spleen was 
removed from one mouse and used for fusion with SP 2/0 as described (15).  Cells were 
cloned on pristane-induced peritoneal exudate cell feeder layers. Anti-Id was selected by 
an  enzyme-linked  immunosorbent  assay  (ELISA)  in  which  K13  Ps  was  coated  onto 
polyvinyl microtiter plates (at 50/~g/ml for 1 h) followed by a 1:50,000 dilution of 150C8- 
containing ascites. At this dilution,  the alkaline-phosphatase-conjugated polyvalent goat 
antiimmunoglobutin (Cappel Laboratories, Cochranville,  PA) reacted very weakly with 
the  150C8  itself and very well after addition of anti-Id. One anti-Id clone,  5868C,  an 
IgG1, was selected for study. Ascites was produced in CAF~ mice. 
Hemagglutination  Inhibition  (HA1).  HAI  was  performed  using  the  chromic chloride 
method of Gold and Fudenberg (16) as described by Lieberman et al. (17) except that 
anti-Id was coated onto the erythrocytes (RBC). Ammonium sulphate-precipitated 5868C 
was used for coating RBC at a concentration of 25 ~g/100 #1. An S-300 (Pharmacia Fine 
Chemicals, Piscataway, N  J) column fraction of 150C8-containing ascites was ammonium 
sulphate precipitated and the purified IgM was used to agglutinate 5868C-coated sheep 
RBC (SRBC).  Titrations consisting of serial twofold dilutions were performed in every 
experiment. The concentration of 150C8 chosen for HAI was two dilutions before the 
endpoint  of agglutination  and  usually  fell  between  10  and  100  ng/ml.  5868C-coated 
SRBC were specifically agglutinated by the IgM idiotype, 1  ~0C8. Another IgM (150B2) 
and two IgG (156E8,  147D11) hybridoma anti-K13 antibodies as well as MOPC  104E 
(IgM~) and  TEPC  183  (IgMK) myeloma proteins (Litton  Bionetics,  Rockville, MD), at 
concentrations of 1 mg/ml, failed to agglutinate 5868C-coated SRBC and to precipitate 
5868C by immunodiffusion. 
Immunizations.  Mice were injected intraperitoneally with 0.2 ml of either 5 #g K13 Ps 
in PBS, 1 x  108 killed K13 bacteria in PBS (K13 vaccine), or 30 #g K13-Hy in CFA, and 
were bled as indicated in Table II. A second immunization was given 1 mo after the first 
as  stated  above  except  that  K13-Hy  was  given  in  IFA.  Mice  primed  at  birth  were 
subsequently given K 13 vaccine or 2.5 ~g K13 Ps in PBS, injected intraperitoneally. Rats STEIN AND  SODERSTROM  1003 
were anesthesized with CO2, immunized intraperitoneally with K 13 vaccine once a month 
for 6 too, and bled 1 wk after the last injection. 
Neonatal Priming.  Mice  were primed within 24 h after birth by an intraperitoneal 
injection  of 50 #1 containing the substances indicated  in Tables  IV and V, diluted in 
sterile, pyrogen-free saline. 
Challenge with E. coll.  Mice  were challenged with 0.5 ml live E. coli 06:K13:H 1 in PBS 
given intraperitoneally  1 wk after immunization when they were 5 wk old (Table IV) or 
13 wk old (Table V). Deaths were recorded 24 h after challenge. The challenge doses are 
given in Tables IV and V. 
Ouchterlony Analysis.  Immunodiffusion was performed in  0.9% agarose  (Indubiose 
A37; Accurate  Chemical and Scientific Corp.,  Hicksville, NY) in PBS. Sera and ascites 
were used undiluted, IgM myeloma and hybridoma proteins at a concentration of 1 mg/ 
ml, and IgG myeloma and hybridoma proteins at a concentration of 0.25 mg/ml. 
Results 
Production  and Characterization  of 5868C Anti-Id.  The sera  of A/HeJ mice 
hyperimmunized with  immune  complexes  of IgM  anti-K13  (150C8)-K13  Ps 
appeared  to  contain  anti-Id  antibodies after  the  5th  wk  of immunization as 
determined by Ouchterlony analysis (data not shown). One mouse was chosen 
for the production of monocional anti-Id. Selection for anti-Id on Id plus antigen 
(K 13 Ps)-coated plates was successful in this instance, probably because not all of 
the combining sites of the IgM Id were bound to antigen. The same technique 
was  not  successful  in  the  selection  of anti-Id  antibodies  reactive  with  IgG 
idiotypes. Several independent clones were derived from this fusion and 5868C, 
an IgG1, was chosen for further study. By Ouchterlony analysis, 5868C precip- 
itates 150C8 but not two IgM myeloma proteins, MOPC  104E and TEPC  183, 
nor does it precipitate with normal mouse serum or a  variety of IgM and IgG 
anti-K13 hybridomas. 
A reverse HAI assay was used to study the effect of antigen on the Id-anti-Id 
reaction and to assess the presence of the 150C8  Id in immune sera. This assay 
was used because Id-coated RBC were not agglutinated by the IgG anti-Id. Table 
I  shows that agglutination of anti-Id (5868C)-coated  RBC by Id (150C8)  was 
specifically inhibited by  K13  and  not  by  two  unrelated  Ps,  K1  and  HIB.  In 
addition, a  weak  inhibition due  to  cross-reactivity, not  seen  by  Ouchterlony 
analysis, was observed with two Ps, K20 and K23, which are very closely related 
to K13. 
Presence of 150C8 Id in Serum.  The 150C8 Id, as detected by HAI, was found 
in both the preimmune and immune sera of three strains of mice that differ at 
the Igh locus: BALB/c, lgha; C57BL/6, Igh  b, and CBA, Igh  j (Table II). Increases 
in Id related to immunization were seen in BALB/c and CBA strains and only 
early after a  primary immunization. In both strains the level of Id declined to 
below preimmune levels at  14 and 21  d  after a primary immunization and 7 d 
after a secondary immunization in BALB/c mice. The same trend was seen in 
C57BL/6 mice, although the differences were not significant. In contrast, two 
of three Sprague-Dawley rats (Table  III) that had been hyperimmunized with 
K13  vaccine showed high levels of 150C8  Id whereas the pooled normal rat 
serum showed no HAI activity. When the presence of the 150C8 Id was followed 
in another group of six Sprague-Dawley rats (data not shown) before and 7,  14, 
and 21  d after a primary, and 7 d after a secondary immunization with K 13, no 1004  NEONATAL  PRIMING  WITH  1DIOTYPE  AND  ANTIID1OTYPE 
TABLE  I 
Inhibition  of ld-anti-ld by Antigen 
HA1 
Polysaccharide  *  titer* 
K13  3)-/3-Ribofuranosyl-(1  ---,  7)-/3-KDO-(2 ~  44 
4 
Acetyl 
K20  3)-/3-Ribofuranosyl-(1  ~  7)-/3-KDO-(2 ---*  5 
5 
Acetyl 
K23 
KI 
HIB 
343-Ribofuranosyl-(1  --* 7)-B-KDO-(2 ~  6 
8)-a-NeuNAc-(2 ~  8)-a-NeuNAc-(2 ~  < 1 
3(-/~-Ribofuranosyl-(l  ~  l)-Ribitol-5-(PO4 ~  <1 
* Ps solutions were used at a starting concentration of 10 mg/ml in saline 
and serial twofold dilutions were used for inhibition. 
* Log 2. 
TABLE  II 
150C8 ld in Mouse Serum 
Strain  Immunogen  Preim- 
mune 
HAI titer* 
Days after immuniza- 
tion 
Second-  Primary  ary 
7  14  21  7 
BALB/cJ  4* 
K13 Ps  7  2  2  2 
K13 vaccine  7  2  2  2 
K13-Hy  6  2  2  2 
CBA/J  3 
K13 Ps  5  3  1  ND  a 
K 13 vaccine  6  2  1  ND 
C57BL/6J n  3 
K13 Ps  4  2  2  ND 
K 13 vaccine  4  4  3  ND 
* Log 2, starting with a  1:2 dilution of serum; sera were pooled from six 
mice per group. 
* A pool of serum from unimmunized BALB/cCu mice was used in place 
of preimmune BALB/cJ serum. 
0 Not done. 
t All sera were absorbed with an equal volume of packed SRBC before 
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TABLE  III 
150C8 Id in Rat Serum 
Serum  HAI titer* 
Pooled NRS*  1 
Rat 1  i  <1 
Rat 2  6 
Rat 3  6 
* Log 2. 
* NRS, normal rat serum. 
0 Rats were hyperimmunized with K13 vaccine over a  period of several 
months. They were bled 1 wk after the last immunization. 
TABLE  IV 
Effect  of  Neonatal  Priming  with  Id  and  Anti-ld  When BALB]c  Mice  Are Challenged 
at 5 Wk of Age 
1005 
Immunization at 4  No. of  Percent 
Exp.  Treatment at birth  wk of age  mice  survival 
1  --*  --  6  0* 
K 13 vaccine  9  44 
K13 Ps, 2.5 #g  K13 vaccine  6  33 
150C8,  1 t~g  KI3 vaccine  15  87 
5868C, 50 ng  K13 vaccine  15  93 
5868C,  10 #g given to mothers after  K13 vaccine  6  83 
delivery! 
2  Saline  KI3 Ps, 2.5 #g  6  0 ! 
KI3 Ps, 2.5 ug  KI3 Ps, 2.5 ~,g  6  33 
150C8,  1 #g  KI3 Ps, 2.5 #g  8  75 
150C8, 50 ng  K13 Ps, 2.5 #g  10  40 
5868C,  1 #g  KI3 Ps, 2.5 #g  5  80 
5868C, 50 ng  KI3 Ps, 2.5 ug  9  78 
* No injection. 
* Mice were challenged with 20 LD~0 live E. coli 06:K13. 
t Anti-ld was injected intraperitoneaily into the mother within 24 h after delivery of her pups. 
I Mice were challenged with 30 LDs0 live E. coli 06:KI 3. 
change was found with immunization.  In this group of rats, titers of 4-6 (log 2) 
were found in individual preimmune  sera and they did not change in immune 
sera at any time. The  150C8 Id was not found in burro and human sera known 
to contain high titers of anti-K13.  It remains to be determined whether the Id 
in C57BL/6 and some rat sera is present on K 13-binding antibodies. 
Effects of  ld and Anti-Id Priming at Birth.  In earlier experiments we had found 
that  150C8  anti-K13  would  confer  passive  protection  against  intraperitoneal 
infection with E.  coli K13  in  mice (18).  We therefore designed experiments to 
determine if either Id (150C8) or anti-Id (5868C), when administered within 24 
h  after birth,  could prime  for protection  against E.  coli K13  infection  in  both 
young mice (5  wk old) and adults (13  wk old).  In  the first experiment  (Table 
IV), mice injected at birth with  150C8 or 5868C and immunized at 4 wk of age 
with  K13  vaccine were significantly  protected from infection  with  20  LDs0 E. 1006  NEONATAL  PRIMING  WITH  IDIOTYPE  AND  ANTIIDIOTYPE 
coli K 13 as compared with controls either uninjected or immunized with K 13 Ps 
at birth.  In addition, this experiment shows that anti-Id can prime for protection 
even when administered  through  milk, i.e., by administration  of anti-Id  to the 
mother within 24 h after delivery. 
To rule out any effects of iipopolysaccharide on the protection,  inasmuch  as 
the mice were given a  whole cell vaccine at  4  wk of age,  the  experiment  was 
repeated,  except that  the  mice were immunized  with  highly purified  K13  Ps. 
Again, both Id and anti-Id were able to prime for protection when the challenge 
dose of E.  coli  was  30  LDs0 (Table  IV).  When  the  time  of immunization  was 
delayed until  12 wk of age (Table V), however, only anti-Id and not Id was able 
to prime for protection. Only the 50 ng dose of 5868C gave a significant priming 
effect, but it should  be noted  that  a  50  LD~0 challenge  dose was used  in  this 
experiment. 
Discussion 
We have shown that a  monoclonal anti-Id (5868C) as well as the Id anti-K13 
Ps  (150C8)  can  prime  neonatal  mice  for  protection  upon  immunization  and 
subsequent challenge with live E. coli K13. The data also show that the priming 
effects of anti-Id can be transferred to pups via the milk as the pups of a mother 
given anti-Id within 24 h after delivery were also protected from challenge with 
E. coli.  The properties of this system that may be important  to the ability of Id 
and anti-Id to prime for protection are that (a)  150C8, itself, can confer passive 
protection  (18),  (b)  150C8  is  bactericidal  in  vitro  (15),  and  (c)  that  the  site 
recognized by 5868C anti-Id is related to the  150C8 combining site because Id- 
anti-Id  is  specifically  inhibited  by  K13  Ps.  Both  Id  and  anti-Id  primed  for 
challenge at 5 wk of age. These studies confirm the results of Rubinstein et al. 
(10,  11) who demonstrated that treatment at birth with A48 (10), a BL-binding 
myeloma protein, or anti-A48 (11), primed for an A48-dominant response upon 
immunization  with  BL  at  4  wk  of age.  Their  experiments  showed  that  the 
administered A48 alone was not responsible for the effect and that immunization 
with antigen was required.  Inasmuch as IgM has a short half-life, a direct effect 
of 150C8, 5 wk after its administration,  is unlikely. 
In our experiments, when immunization  was delayed until  12 wk of age, only 
TABLE  V 
Effect of ld and Anti-ld Priming When BALB/c Mice Are Challenged 
at 13 Wk of Age 
Treatment at birth  Immunization at 12  No. of  Percent 
wk of age  mice  survival* 
--*  --  9  0 
--  K13 Ps, 2.5 #g  20  25 
150C8,  1 #g  --  5  0 
150C8,  1 #g  KI3 Ps, 2.5 #g  27  22 
5868C,  1 gg  K13 Ps, 2.5 #g  19  16 
5868C, 50 ng  K13 Ps, 2.5 #g  30  78 
*  Mice were challenged with 50 LDs0 live E.  coli 06:K13. 
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the mice primed with anti-Id were protected. In the experiment shown in Table 
V, 50 ng but not  1 #g of 5868C primed for protection. The reason for the lack 
of priming by 1 #g of 5868C is unknown but it may reflect a dose effect of anti- 
Id. Experiments involving 5868C priming of adult mice indicated that nanogram 
quantities of 5868C primed for anti-K 13 whereas microgram quantities, depend- 
ing  on  the  amount,  either  did  not  prime  or  primed  for  Id  on  non-antigen- 
binding molecules (T. S6derstr6m and K. E. Stein, unpublished). The differences 
seen in the effects of neonatal  Id and anti-Id priming  on the adult response to 
challenge may reflect differences in the cell populations being stimulated by Id 
and anti-Id.  Rubinstein et al. (10,  11) have shown that the effects of Id priming 
can be transferred to unprimed animals by helper T  cells (Th) (10), but that the 
effects of anti-Id priming  can be transferred by B cells (11).  We speculate that 
the  primed  B  cells (by anti-Id)  are  long-lived  whereas  the  Id-specific Th  cells 
either  are  short-lived  or  fail  to  be  expanded  during  environmental  antigen 
exposure. This would be the case if the  150C8 Id were not a dominant Id in the 
response to K13; we have no data to suggest that it is. 
Both in mice (4, 5) and in man (6-8), the immune response to TIPs antigens 
develops  relatively  late  in  ontogeny  although  responses  to  TD  antigens  are 
present at birth  (9).  The development of responses to Ps antigens parallels  the 
development of a  subset of B cells in mice,  Lyb-5  + cells, regardless of whether 
the Ps is presented in a TI or TD form (9).  One explanation  proposed by Stein 
et al. (9) for the failure of neonates to respond to Ps antigens was that the Lyb- 
5- B cells present in the neonate are tolerized by exposure to environmental Ps. 
The data presented here, as well as the data of Rubinstein  et al.  (11) showing 
that  anti-Id  given  within  24  h  after  birth  can  prime  for a  subsequent anti-Ps 
response, coupled with the additional findings of Rubinstein et al. (11) that the 
priming  effect of anti-Id  can  be transferred  to adoptive recipients  by B  cells, 
strongly suggest that B cells are present at birth that have surface Ig specific for 
Ps antigens.  These  cells would be activated  by anti-Id  such  that  they become 
refractory to the tolerizing effects of environmental  Ps. The implication  is that 
if the B cells present at birth can be activated before exposure to environmental 
Ps, they will  respond,  rather  than  be tolerized,  upon subsequent antigen  expo- 
sure. 
To our knowledge, this is the first demonstration of the ability ofa monoclonal 
anti-Id  antibody  to  prime  for protection  against  a  microbial  infection.  These 
experiments show that a monocional anti-Id, directed against a single site on an 
anti-K 13 antibody, can alter the entire biological response to a bacterial infection 
so that mice primed with anti-Id survive challenge with live E. coli K13, whereas 
unprimed mice die. Polyclonai anti-Id priming has been shown to induce protec- 
tion  in  adult  mice  against  trypanosomiasis  (19)  and  to  induce  neutralizing 
antibodies  against  rabies  virus  (20)  and  antibodies  to  the  surface  antigen  of 
hepatitis B virus (21) in mice. It seems likely that in infections where antibodies 
are  protective  and  can  be induced  by anti-Id  reagents,  anti-Id  antibodies  can 
induce  or  prime  for  protection.  The  use of anti-Id  antibodies  as  vaccines  in 
human infants, however, is not yet practical. 
Our data suggest that  Id, or passive antibody, can also prime for protection 
when antigen is encountered early in life. Although the priming effect of Id was 1008  NEONATAL  PRIMING  WITH  IDIOTYPE  AND  ANTIlDIOTYPE 
not seen in  mice challenged as adults, priming is not as important at this age 
inasmuch as adults respond well to Ps antigens. Passive antibody of protective 
idiotypes could thus have a  dual effect in infants: it would provide immediate 
passive protection and it could prime for subsequent exposure to antigen. The 
concept of passive antibody protection of newborns is not a new one. In  1951, 
Cohen, Schneck, and Dubow (22) immunized pregnant women against diphtheria 
and  pertussis  and  measured the  levels of antibodies  in  infants born  of these 
mothers. They found that the infants had protective levels of antibodies for a 
period of 3 mo and they advocated immunization of these infants at 4 mo of age, 
a time when most of the maternal antibody was gone. The possibility of a priming 
effect of maternal antibody was suggested by the data of Levi et ai. (23) which 
showed that the response to vaccination with pertussis-diphtheria-tetanus vaccine 
is greater in babies with antibodies in the cord blood. More recently, Gill et ai. 
(24)  immunized pregnant  women with  tetanus toxoid and found that  infants 
whose mothers were immunized responded better to subsequent immunization 
than infants of unimmunized mothers. Maternal antibody may not always have 
a priming effect. When high cord blood antibody levels exist and immunization 
is performed at a young age (2 mo), reduced responses may be seen, as reported 
by Burstyn et al. (25) for IgG antibodies to the leukocytosis-promoting toxin of 
Bordetella pertussis.  A similar finding was reported by Osborn, Dancis, and Julia 
(26) on the effects of circulating antibody in the response to diphtheria toxoid. 
In contrast, McCormick et al. (27) found that children born of mothers immu- 
nized during pregnancy with meningococcal groups A and C Ps respond as well 
to  these antigens as  children born  of unvaccinated mothers.  These children, 
however, were immunized at 6 mo of age, when maternal antibodies had declined 
to levels indistinguishable from those in children born of unvaccinated mothers. 
Taken together, the data suggest that immunization of infants with high levels 
of maternal antibody should be delayed until a time when the antibody level has 
declined substantially.  The role of maternal antibody, as opposed to immune 
gamma globulin from unrelated donors, may be important for Id-anti-Id regu- 
lation if such regulation requires the presence of allotype-linked Igh-V genes, as 
was recently demonstrated for the anti-Id induction of protection against trypa- 
nosomiasis by Sacks and Sher (28). The priming effect of maternal antibody on 
immune responses in infants with regard to Ps antigens as compared with protein 
antigens remains to be investigated. We suggest that the role of network regu- 
lation via Id-anti-Id interactions will see increasing study as protective idiotypes 
are described in man. 
Summary 
Antibodies directed against the capsular polysaccharides (Ps) of encapsulated 
pathogenic bacteria can protect the host against infection with such organisms. 
The immune response to Ps, however, does not develop until relatively late in 
ontogeny.  We  have,  therefore,  studied  alternative  ways  to  stimulate  anti-Ps 
antibody responses in neonates, namely priming with idiotype (Id) and anti-Id. 
We believe that these studies provide the first demonstration of the use of an 
anti-Id antibody to prime for protection against a bacterial infection and the first 
demonstration of the ability of a  monoclonal anti-Id  to  prime  for protection STEIN  AND  SODERSTR6M  1009 
against any microbial infection. We have used a  monoclonal IgM  Id, anti-K13 
capsular  antibody,  and  a  monoclonal  IgG1  anti-Id  in  studies  of the  effects of 
administration of anti-Id or Id within 24 h  after birth on the ability of mice to 
respond  to  subsequent  immunization  and  challenge  with  live  bacteria.  These 
studies show that neonatal administration of 1 ug of Id or 50 ng of anti-Id lead 
to  significantly  enhanced  protection  in  mice  immunized  at  4  wk  of age  and 
challenged at  5  wk  with  an  intraperitoneal  injection of 20-30  LDs0 of E.  coli 
06:K13:H 1, as compared with unprimed or antigen (Ps)-primed controls.  Mice 
primed at birth, immunized at  12 wk of age, a time when they can respond fully 
to Ps itself, and challenged  1 wk later, were still significantly protected by anti- 
Id priming but no longer showed the effects of Id. We conclude that administra- 
tion of protective Id early in life may serve a dual function in providing immediate 
passive protection as well as priming for protective antibodies upon subsequent 
antigen exposure. 
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Note  added  in proof'. H.  Kohler,  M.  McNamara,  and  R.  E.  Ward  have  shown  that 
immunization of BALB/c mice with 4C11, a monoclonal anti-Id T15, that was coupled 
to keyhole limpet hemocyanin, led to enhanced survival after infection with Streptococcus 
pneumonia.  In The Molecular Basis of Cancer. R.  Rein, editor. Alan R. Liss, Inc., New 
York. In press. 
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